Pressreleaser | 17 Nov 2022 | Scandinavian Chemotech

ChemoTech: Important update regarding cancer patients treated with IQwave™ Tumour Specific Electroporation™ (TSE) at Ulis Hospital Ukraine

The previously published press release stated that one of the pancreatic cancer patients had received conventional chemotherapy with limited response. The tumour was deemed unresectable when Chemotech’s TSE treatment with IQwave under open surgical procedure was chosen as an alternative. After the promising results, the team performed the TSE treatment on yet another patient with pancreatic cancer.

Ulis Hospital now reports that these pancreatic cancer patients have shown an almost 50% decrease in tumour mass. Both patients are mobile and capable of self-care, in no pain and therefore in no needofpainrelief.

The third patient with skin cancer in the groin (inguinal squamous cell carcinoma) has had almost a complete response with TSE, avoiding surgery altogether. A low dose of radiotherapy is currently being given as a precaution for any residual tumour. 

Additionally, the oncology team at Ulis Hospital has also treated one case of tonsillar cancer, which is still to be followed up on and is about to treat a case of locally advanced breast cancer.

”Our two pancreatic cancer patients have shown encouraging results so far. The inguinal skin cancer case has done exceptionally well, and surgery could be avoided. We are happy with the overall performance of the TSE technology. ”- says Alexei Kovalev, Professor at Ulis Hospital

”The results have been highly reassuring and the medical team at ChemoTech will continue to observe the data meticulously for safety, efficacy, and additional indications.” – says Dr Suhail Mufti, Medical of Director Scandinavian ChemoTech

”I can see the IQwave™ TSE technology performing exceptionally well in not only skin cancers but also in difficult-to-treat pancreatic tumours, which is a proof of concept for its application in deep-seated solid tumours. The R&D team at ChemoTech are at work to support clinicians in approaching these deep-seated tumours with minimally invasive approaches.” – says Mohan Frick, CEO of Scandinavian ChemoTech

This disclosure contains information that ChemoTech is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 17-11-2022 20:45 CET.